View in EDS HTML Full Text PDF Full Text

Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes.
Authors: Song, Ji Hun1 (AUTHOR) dreyesong@naver.com, Kim, Chungwoon1 (AUTHOR), Chung, Yoo-Ri1 (AUTHOR), Kim, Hae Rang1 (AUTHOR)
Source: Journal of Clinical Medicine. Nov2025, Vol. 14 Issue 22, p8179. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20770383
DOI:10.3390/jcm14228179